Aspirin resistance in Thai patients with chronic stable angina

Rewat Phankingthongkum1, Pradit Panchavinnin, Yingyong Chinthammitr

  • 1Division of Cardiology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. rewat.pha@mahidol.ac.th

Insights

Aspirin resistance affects 21.6% of Thai patients with chronic stable angina. This study found no significant clinical risk factors associated with aspirin resistance in this patient group.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Aspirin is a cornerstone therapy for chronic stable angina.
  • Aspirin resistance is a growing concern, potentially impacting treatment efficacy.
  • Understanding aspirin resistance prevalence and risk factors is crucial for optimizing patient care.

Purpose of the Study:

  • To determine the prevalence of aspirin resistance in Thai patients with chronic stable angina.
  • To identify clinical profiles and potential risk factors associated with aspirin resistance.

Main Methods:

  • Prospective recruitment of 157 patients diagnosed with chronic stable angina.
  • Blood samples analyzed for hemoglobin, platelet count, and platelet aggregation using light transmittance aggregometry.
  • Aspirin resistance defined by specific thresholds for adenosine diphosphate (ADP) and arachidonic acid-induced platelet aggregation.

Main Results:

  • The prevalence of aspirin resistance was 21.6% (34 out of 157 patients).
  • Patients with aspirin resistance had a mean age of 66 years, with 58.8% being male.
  • No statistically significant association was found between aspirin resistance and factors like age, gender, BMI, diabetes, hypercholesterolemia, smoking, or PPI use.

Conclusions:

  • The prevalence of aspirin resistance in Thai patients with chronic stable angina is 21.6%.
  • No significant associations were identified between common clinical factors and aspirin resistance in this cohort.
  • Further research may be needed to explore other potential contributors to aspirin resistance.
Abstract

Related Concept Videos

Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...